Mason W Freeman

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Diabetes, obesity & metabolism

Massachusetts General Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Massachusetts General Hospital

United States

Professor :: Center for Computational & Integrative Biology

Publications

John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism 26 (3) (2023)
John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism 26 (3) (2023)
Yuan-Di C Halvorsen, Annie L Conery, John Paul Lock, Wenjiong Zhou, Mason W Freeman
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism (2023)
John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism (2023)
John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism (2023)
Yuan-Di C Halvorsen, John Paul Lock, Juan Pablo Frias, Francisco José Tinahones, Dominik Dahl, Annie L Conery, Mason W Freeman
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, obesity & metabolism (2022)
Yuan-Di C Halvorsen, Geoffrey A Walford, Joseph Massaro, Robert P Aftring, Mason W Freeman
A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes, obesity & metabolism 21 (11) (2019)
Yuan-Di Halvorsen, Geoffrey Walford, Tara Thurber, Heidy Russell, Monica Massaro, Mason W Freeman
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes, obesity & metabolism 22 (4) (2019)
Yuan-Di Halvorsen, John P Lock, Wenjiong Zhou, Fang Zhu, Mason W Freeman
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, obesity & metabolism 21 (10) (2019)

Mason W Freeman.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mason W Freeman